In order to find novel compounds with superior antitumor activity, a series of 6-(N-imide)-β-carboline derivatives with diverse substituents, totaling 30 compounds, were designed and synthesized. The inhibitory effects of these compounds on five cancer cell lines, namely lung cancer (A549), gastric cancer (BGC-823), colon cancer (CT-26), liver cancer (Bel-7402), and breast cancer (MCF-7), were evaluated using methyl thiazolyl tetrazolium (MTT) assay. The experimental results indicated that most target compounds exhibit better antitumor activity against the tested cell lines, with half-maximal inhibitory concentrations (IC50) values below 20 μmol/L. Moreover, the series of compounds showed better inhibitory activity against the A549 and Bel-7402 cell lines. In particular, compounds 5j, 5p, and 5ac exhibited excellent inhibitory activity against tumor cells, demonstrating potential value for antitumor research. Specifically, compounds 5j and 5p exhibited excellent inhibitory activity against the A549, BGC-823, and Bel-7402 cell lines, while compound 5ac showed excellent inhibitory activity against the A549, Bel-7402, and MCF-7 cell lines, all with IC50 values less than 10 μmol/L. The molecular docking results indicate that compound 5ac exhibits favorable binding interactions with multiple amino acid residues of vascular endothelial growth factor receptor-2 (VEGFR-2).